Aicardi–Goutières syndrome and the type I interferonopathies
The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Dissection of the genetic basis of Aicardi-Goutières syndrome has highlighted a fundamental link between nucleic acid metabolism, innate immune sensors and type I interferon induction. This had led to the concept of the human interferonopathies as a broader set of Mendelian disorders in which a constitutive upregulation of type I interferon activity directly relates to disease pathology. Here, we discuss the molecular and cellular basis of the interferonopathies, their categorization, future treatment strategies and the insights they provide into normal physiology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ADAR edits Alu RNA51, and gain of function mutations in MDA5 suggest that RNA-sensing mechanisms are involved in some AGS cases119.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [119]
In the citing paper
“Aicardi–Goutières syndrome (AGS) is a childhood encephalopathy with similarities to SLE and strong IFN-I induction119.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [119]
In the citing paper
“In fact, hypocomplementia is a common feature of type I interferonopathies66,67”
From Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation (2017) · cites this paper as [66]
In the citing paper
“For example, deficits in RNASEH2, an enzyme responsible for removing ribonucleotides from DNA and resolving R‐loops, comprise more than half of AGS diagnoses (Crow & Manel, 2015).”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Crow & Manel, 2015
In the citing paper
“AGS is caused by mutations in genes that regulate nucleic acid metabolism.”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Crow & Manel, 2015
Citations
Cites
1 retracted
MAVS, cGAS, and endogenous retroviruses in T-independent B cell responses
Zeng, M., Hu, Z., Shi, X., Li, X., Zhan, X., Li, X.-D., Wang, J., Choi, J. H., Wang, K.-W., Purrington, T., et al. (2014) · Science · doi:10.1126/science.346.6216.1486 · Cited by 112
RetractedMitochondrial DNA stress primes the antiviral innate immune response
West, A. P., Khoury-Hanold, W., Staron, M., Tal, M. C., Pineda, C. M., Lang, S. M., Bestwick, M., Duguay, B. A., Raimundo, N., MacDuff, D. A., et al. (2015) · Nature · doi:10.1038/nature14156 · Cited by 1,975
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx
Laguette, N., Sobhian, B., Casartelli, N., Ringeard, M., Chable-Bessia, C., Ségéral, E., Yatim, A., Emiliani, S., Schwartz, O., & Benkirane, M. (2011) · Nature · doi:10.1038/nature10117 · Cited by 1,511
Activated STING in a Vascular and Pulmonary Syndrome
Liu, Y., Jesus, A. A., Marrero, B., Yang, D., Ramsey, S. E., Montealegre Sanchez, G. A., Tenbrock, K., Wittkowski, H., Jones, O. Y., Kuehn, H. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312625 · Cited by 1,412
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379
Trex1 prevents cell-intrinsic initiation of autoimmunity
Stetson, D. B., Ko, J. S., Heidmann, T., & Medzhitov, R. (2008) · Cell · doi:10.1016/j.cell.2008.06.032 · Cited by 1,280
Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein
Hrecka, K., Hao, C., Gierszewska, M., Swanson, S. K., Kesik-Brodacka, M., Srivastava, S., Florens, L., Washburn, M. P., & Skowronski, J. (2011) · Nature · doi:10.1038/nature10195 · Cited by 1,200
Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production
White, M. J., McArthur, K., Metcalf, D., Lane, R. M., Cambier, J. C., Herold, M. J., van Delft, M. F., Bedoui, S., Lessene, G., Ritchie, M. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.036 · Cited by 983
Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature
Rice, G. I., Kasher, P. R., Forte, G. M. A., Mannion, N. M., Greenwood, S. M., Szynkiewicz, M., Dickerson, J. E., Bhaskar, S. S., Zampini, M., Briggs, T. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2414 · Cited by 923
Self-citationImmune Interferon in the Circulation of Patients with Autoimmune Disease
Hooks, J. J., Moutsopoulos, H. M., Geis, S. A., Stahl, N. I., Decker, J. L., & Notkins, A. L. (1979) · New England Journal of Medicine · doi:10.1056/nejm197907053010102 · Cited by 921
Research works printed but not linked: 1
- Krivine, A., Tovey, M., Taty-Taty, R. & Lebon, P. Endogenous interferon-α in newborns from HIV seropositive mothers. J. Interferon Res. 12, S151 (1992).
Cited by
Items 601–700 of 931
Fukushi, M., Ohsawa, R., Okinaka, Y., Oikawa, D., Kiyono, T., Moriwaki, M., Irie, T., Oda, K., Kamei, Y., Tokunaga, F., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287545 · Cited by 8
Gagne, S. J., Sivaraman, V., & Akoghlanian, S. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1169638 · Cited by 6
“The US Food and Drug Administration’s Compassionate Use Program was initiated in 2011 to treat pediatric patients with rare Mendelian autoinflammatory diseases that have IFN-mediated pathology (3, 11).”
BackgroundGutiérrez-Chamorro, L., Felip, E., Castellà, E., Quiroga, V., Ezeonwumelu, I. J., Angelats, L., Esteve, A., Perez‐Roca, L., Martínez‐Cardús, A., Fernández, P. L., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00862-1 · Cited by 9
“Recently, the human sterile alpha motif and HD-domain-containing protein 1 (SAMHD1) has been linked to cancer onset and progression, as well as to chemosensitivity to distinct anticancer drugs, with numerous and controversial evidences [24–27].”
BackgroundMoadab, F., Sohrabi, S., Wang, X., Najjar, R., Wolters, J. C., Jiang, H. L., Miao, W., Romero, D. L., Zaller, D. M., Tran, M., et al. (2024) · Mobile DNA · doi:10.1186/s13100-024-00324-x · Cited by 6
White matter disorders with cerebral calcification in adulthood
Chelban, V., & Houlden, H. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-99209-1.00024-7 · Cited by 6
Aggravating mechanisms from COVID-19
Lee, J., Sergi, C. M., Kast, R. E., Kanwar, B. A., Altschuler, E. L., Bourbeau, J., Sohn, M.-G., Sohn, M.-G., Lee, K. H., & Coleman, M. D. (2024) · Virology Journal · doi:10.1186/s12985-024-02506-8 · Cited by 6
Nitrofuran-Based STING Inhibitors
Barasa, L., DeOrsey, L., O’Reilly, M. D., Choudhary, S., Cahill, S. E., Mathur, A., Rajoria, S., Green, R. M., Allabaji, A., Nellikkalaya, S., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c05578 · Cited by 6
Single-cell analysis of signalling and transcriptional responses to type I interferons
Rigby, R. E., Rue-Albrecht, K., Fedorov, A., Sims, D., & Rehwinkel, J. (2026) · EMBO Reports · doi:10.1038/s44319-026-00750-3 · Cited by 10
“However, in some autoimmune and autoin fl ammatory conditions, type I IFNs are secreted chronically and initiate and/or exacerbate disease (Crow and Manel, 2015).”
Endo, Y., Koga, T., Otaki, H., Furukawa, K., & Kawakami, A. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108732 · Cited by 6
Jütte, B. B., Krollmann, C., Cieslak, K., Koerber, R.-M., Boor, P., Graef, C. M., Bartok, E., Wagner, M., Carell, T., Landsberg, J., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102833 · Cited by 6
“In humans, loss-of-function mutations in TREX1 are associated with Aicardi-Goutieres syndrome, familial chilblain lupus, and systemic lupus erythematosus (Crow and Manel, 2015).”
BackgroundWang, Y., Lin, S., Wu, J., Jiang, M., Lin, J., Zhang, Y., Ding, H., Zhou, H., Shen, N., & Di, W. J. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0965-7 · Cited by 7
“Moreover, dysregulated IFN-I signaling could be pathogenic and detrimental to fetal survival [31,32] and could be even more so under the condition of SLE because the disease per se is distinguished by the overactivation of the IFN-I signaling pathway [4].”
BackgroundVasco, V. R. L. (2023) · OBM Geriatrics · doi:10.21926/obm.geriatr.2302234 · Cited by 6
Investigation of immune-related diseases using patient-derived induced pluripotent stem cells
Shoda, H., Natsumoto, B., & Fujio, K. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00303-4 · Cited by 8
Nucleic acid-mediated autoinflammation and autoimmunity—type I interferonopathies
Lee‐Kirsch, M. A., Günther, C., & Roers, A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1467-3 · Cited by 6
“While the clinical spectrum of the type I interferonopathies is highly variable and broad, neurological and cutaneous manifestations represent the most salient findings [7, 8].”
BackgroundDevelopment of novel highly sensitive methods to detect endogenous cGAMP in cells and tissue
Miyakawa, S., Okui, T., Shiraishi, T., Yoshihara, T., Hirayama, M., Satomi, Y., Hamada, T., Nishida, M., Akimoto, C., & Sato, S. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112751 · Cited by 8
Guo, J., Li, M., Zhang, Y., Xi, L., & Cui, F. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp05871h · Cited by 6
Inborn Errors of Immunity With Fetal or Perinatal Clinical Manifestations
Carneiro-Sampaio, M. M. S., de Jesus, A. A., Bando, S. Y., & Moreira‐Filho, C. A. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.891343 · Cited by 6
“Type 1 Interferonopathies Aicardi–Goutières syndrome (AGS) represents the prototype of this group of monogenic diseases characterized by a constitutive upregulation of Type 1 IFN (78, 79).”
BackgroundInfluentialSignaling a link between interferon and the traits of Down syndrome
Kirsammer, G. T., & Crispino, J. D. (2016) · eLife · doi:10.7554/elife.20196 · Cited by 6
“Intriguingly, a number of Down syndrome traits resemble the symptoms of hyperactive interferon signaling disorders, termed “interferonopathies” (Crow and Manel, 2015).”
BackgroundSpecialty Grand Challenge In Pediatric Infectious Diseases
Lepage, P., & Blumental, S. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00185 · Cited by 7
“In these specific syndromes linked for example to a defect or a gain of function in interferon pathways (46, 47), the auto-inflammatory pattern can be the inaugural or even unique feature of the disease and seriously impairs patient’s growth and quality of life.”
BackgroundKalvakolanu, D. V. (2017) · Cytokine · doi:10.1016/j.cyto.2017.08.008 · Cited by 7
Alsharief, A. N., Laxer, R. M., Wang, Q., Stimec, J., Man, C., Babyn, P., & Doria, A. S. (2020) · Insights into Imaging · doi:10.1186/s13244-020-00889-0 · Cited by 6
Guarnieri, J. W., Topper, M. J., Beigel, K., Haltom, J., Chadburn, A., Frere, J. J., An, J., Cope, H., Borczuk, A., Sinha, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.08.561395 · Cited by 6
“Such mutations of canonical immune genes produce Aicardi–Goutières syndromes (AGS) wherein overexpression of IFN-signaling genes results in constitutive cytokine-storm and often lethal outcomes in children 47 ( Fig.”
BackgroundEnokizono, M., Kurokawa, R., Yagishita, A., Nakata, Y., Koyasu, S., Nihira, H., Kuwashima, S., Aida, N., Kono, T., & Mori, H. (2023) · Japanese Journal of Radiology · doi:10.1007/s11604-023-01493-0 · Cited by 6
“Many, previous studies have advocated the use of the more generic term, type I interferonopathy (IFN), to refer to this group of monogenic diseases because the upregulation of type I interferon is a crucial aspect of its pathogenesis [50].”
BackgroundAUP1 and UBE2G2 complex targets STING signaling and regulates virus-induced innate immunity
Wang, X., Zhu, X., Lian, Z.-H., Liu, Q., Yan, H., Qiu, Y., & Ge, X. (2025) · mBio · doi:10.1128/mbio.00602-25 · Cited by 6
“In addition to playing a crucial role in protecting the host from DNA pathogens, STING is also involved in autoimmune diseases caused by self-DNA, such as Aicardi–Goutieres syndrome, systemic lupus erythematosus, and other type I interferonopathies (14, 15).”
The cGAS-STING pathway in aging and neurological diseases: From mechanisms to treatment
Li, Y., Chen, Y., Liu, Y., Wang, C., Fu, X., & Ren, M. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111978 · Cited by 7
Zhou, Y., Ji, H., Zhang, Y., Liu, Y., Ning, Y., & Li, P. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1666965 · Cited by 5
“This results in severe type I interferonopathy (Crow and Manel, 2015).”
ER-tethering directs TREX1 penetration of a BAF-dependent barrier at micronuclei
Chen, Y., Norman, R. M., Toufektchan, E., Luan, X., Shim, A., Rosenberg, H., Kovacs, M. T., Nichols, A., Hickling, J. H., Cifani, P., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.02.012 · Cited by 8
Glycosylation as a dynamic regulator of RLR and cGAS-STING innate immune signalling pathways
Tong, J., Zhang, W., Xue, M., & Zheng, C. (2026) · Communications Biology · doi:10.1038/s42003-026-09767-9 · Cited by 7
SP1/RNASEH2A accelerates the development of hepatocellular carcinoma by regulating EMT
Hao, Y., Zou, R., Tao, J., Jiang, M., & Li, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18127 · Cited by 5
Pharmacological potential of cyclic nucleotide signaling in immunity
Ednacot, E. M. Q., Nabhani, A., Dinh, D. M., & Morehouse, B. R. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108653 · Cited by 5
The interferon response at the intersection of genome integrity and innate immunity
Duzanic, F. D., & Penengo, L. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103786 · Cited by 6
Cyr, P., Fader, L. D., Burch, J. D., Pike, K. A., Sietsema, D. V., Boily, M.-O., Ciblat, S., Sgarioto, N., Skeldon, A. M., Gaudreault, S., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00471 · Cited by 5
Cystatin F-a key player in central nervous system disease
Wang, Y.-T., Li, Q., Liu, J., Chen, C., Ding, H.-X., Zha, X., & Zhang, K. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03526-z · Cited by 5
Primary Immunodeficiency and Thrombocytopenia
Mohtashami, M., Razavi, A., Abolhassani, H., Aghamohammadi, A., & Yazdani, R. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2020.1868454 · Cited by 6
Silva, A. M., & Postler, T. S. (2021) · International review of cytology · doi:10.1016/bs.ircmb.2021.02.003 · Cited by 5
Tsai, K., Lee, Y., Chen, B.-Y., Wu, L., Liang, S.-Y., Liu, M., Hung, Y., Hsu, H.-L., Chen, P.-Q., Shieh, J., et al. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.78279 · Cited by 7
“Mutations of the SAMHD1 gene have been identified in AG syndrome [26].”
Técher, H. (2024) · BioEssays · doi:10.1002/bies.202400066 · Cited by 6
Ablasser, A. (2016) · Nature Immunology · doi:10.1038/ni.3397 · Cited by 5
Cyclic Dinucleotides in the Scope of the Mammalian Immune System
Mankan, A. K., Müller, M., Witte, G., & Hornung, V. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_5002 · Cited by 6
Measuring the Levels of Ribonucleotides Embedded in Genomic DNA
Meroni, A., Nava, G. M., Sertic, S., Plevani, P., Muzi-Falconi, M., & Lazzaro, F. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7306-4_22 · Cited by 5
Mino, T., & Takeuchi, O. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20171980 · Cited by 6
“Given that dysregulated production of type IFNs is the cause of type I interferonopathy, NSD3 in addition to TBK1 and IKKε appear to be required for tight control of innate immunity (Crow and Manel, 2015).”
BackgroundProgress towards precision medicine for lupus: the role of genetic biomarkers
Anaya, J., Leon, K. J., Rojas, M., Rodríguez, Y., Pacheco, Y., Acosta‐Ampudia, Y., Monsalve, D. M., & Ramírez-Santana, C. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1448266 · Cited by 6
van Eyk, C. L., Samaraweera, S. E., Scott, A., Webber, D. L., Harvey, D. P., Mecinger, O., O’Keefe, L. V., Cropley, J. E., Young, P. E., Ho, J. W. K., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz096 · Cited by 5
Genetic Variants and Protective Immunity against SARS-CoV-2
Rabaan, A. A., Mutair, A. S. A., Aljeldah, M. M., Shammari, B. R. A., Sulaiman, T., Alshukairi, A. N., Alfaresi, M. S., Al-Jishi, J. M., Bati, N. A. A., Al-Mozaini, M., et al. (2022) · Genes · doi:10.3390/genes13122355 · Cited by 5
“The skin lesions observed in familial chilblain lupus and Aicardi–Goutières syndrome, which are monogenic illnesses characterised by gene variations leading to an enhanced type I IFN response, are mimicked by pandemic-associated pernio (‘COVID toes’) [16].”
BackgroundSubacute Partially Reversible Leukoencephalopathy Expands the Aicardi–Goutières Syndrome Phenotype
de Barcelos, I. P., Bueno, C., Godoy, L. F. D. S., Pessoa, A. L. S., Costa, L. A., Monti, F. C., Cabral, K. S. S., Listik, C., dos Santos, D. D. C., Della‐Ripa, B., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13081169 · Cited by 5
“Their functional compromise either induces 1-IFN production or upregulation of interferonstimulated genes, collectively called interferonopathy [16].”
BackgroundMaestra, S. L., Fròsina, G., Micale, R. T., D’Oria, C., Garibaldi, S., Daga, A., Pulliero, A., & Izzotti, A. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0535-3 · Cited by 6
Nündel, K., & Marshak‐Rothstein, A. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.08.003 · Cited by 5
TREM2 R47H exacerbates immune response in Alzheimer’s disease brainPreprint
Korvatska, O., Kiianitsa, K., Ratushny, A., Matsushita, M., Beeman, N., Chien, W.-M., Satoh, J.-I., Dorschner, M., Keene, C., Bammler, T., et al. (2018) · bioRxiv · doi:10.1101/499319 · Cited by 4
“19 Aicardi-Goutières syndrome (AGS), a group of monogenic interferonopathies that affect the CNS (58).”
BackgroundGuo, Y., Wang, Y., Wang, Y., Liu, Y., Liu, J., Shen, Y., Cao, A.-P., Wang, R., Xie, B.-Y., Pan, X., et al. (2025) · Biomolecules · doi:10.3390/biom15030329 · Cited by 5
Neuronal TDP-43 pathology drives astrocytic interferon response in a mouse model of ALS
An, J., Hendricks, N. E., Wheeler, J. M., Hincks, J. C., Benitez, J. A. R., Snyder, J. M., Kraemer, B. C., Liachko, N. F., & Elkon, K. B. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03658-2 · Cited by 5
Development of UM-200: A Novel Alkyne Amide-Based Inhibitor of the cGAS-STING Pathway
Barasa, L., DeOrsey, L., O’Reilly, M. D., Choudhary, S., Cahill, S. E., Mathur, A., Allabaji, A., Nellikkalaya, S., Paul, S., Vidadala, S. R., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00237 · Cited by 4
Spotlight on cGAS-STING: role in disease pathogenesis and therapeutic potential
Yan, D., Hu, J., Liu, Z. H., & Ouyang, W. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00478-5 · Cited by 4
Therapeutic targeting of the cGAS-STING pathway in human disease
Mahajan, A. S., Forsyth, C. M., Phung, C. D., Shen, X., Jarvis, R., & Stegh, A. H. (2026) · Journal of Clinical Investigation · doi:10.1172/jci204547 · Cited by 8
“Pathogenic cGAS-STING activation drives chronic type I IFN signaling and inflammatory pathology across diverse human diseases (87, 88).”
Rare Causes of Arterial Hypertension and Thoracic Aortic Aneurysms—A Case-Based Review
Encică, S., Molnar, A., Manolé, S., Filan, T., Oprița, S., Bursaşiu, E., Vulturar, R., & Damian, L. O. (2021) · Diagnostics · doi:10.3390/diagnostics11030446 · Cited by 4
“Of interest, PRKG1 is a novel negative regulator of osteoblast differentiation in human skeletal stem cells, and PRKG1 was found to have increased expression in idiopathic scoliosis, where it may become a therapeutic target [36,37].”
BackgroundSpracklen, T. F., Akhalwaya, S., Ackermann, S., Uggenti, C., Seabra, L., Crow, Y. J., & Webb, K. (2025) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.63978 · Cited by 5
Self-citationZNF593 regulates the cGAS-mediated innate immune response by attenuating cGAS-DNA binding
Bai, X., Dong, N., Cao, N., Zhou, M., Yuan, J., Zhang, Y., Liu, Y., Zhang, J., Chen, T., Liu, F., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01508-5 · Cited by 7
STING: a multifaced player in cellular homeostasis
Song, K., Heng, L., & Yan, N. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddae175 · Cited by 4
SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis
Gutiérrez-Chamorro, L., Felip, E., Bernat‐Peguera, A., Ezeonwumelu, I. J., Teruel, I., Martínez‐Cardús, A., Clotet, B., Riveira‐Muñoz, E., Romeo, M., Vila, M. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1112761 · Cited by 4
“Indeed, in agreement with our data, SAMHD1-deficiency and subsequent accumulation of endogenous RNA substrates is a cause of type I interferonopathies, characterized by an upregulation of distinct IFN-stimulated genes (ISGs) (20, 24).”
Ufer, F., Ziegler, S. M., Altfeld, M. A., & Friese, M. A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1118369 · Cited by 4
“Under the hypothesis—later turned out to be incorrect—of a pathological accumulation of intracellular retroviral elements due to an impaired function of the exonuclease activity of TREX1 (3), we treated this index patient with a combination of anti-retroviral drugs (emtricitabine, tenofovir, nevirapine) (Figure 1, Sup…”
BackgroundAlwardat, S., Frassinelli, L., Orecchini, E., Rey, F., Ciafrè, S. A., Galardi, S., Garau, J., Gagliardi, S., Orcesi, S., Tonduti, D., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.05.020 · Cited by 4
Innate immune sensing of macromolecule homeostasis
Yang, K., Jeltema, D., & Yan, N. (2024) · Advances in immunology · doi:10.1016/bs.ai.2024.03.004 · Cited by 4
Nonverbal Cognitive Skills in Children With Aicardi Goutières Syndrome
Gavazzi, F., Vaia, Y., Woidill, S., Formanowski, B. L., de Barcelos, I. P., Sevagamoorthy, A., Modesti, N. B., Charlton, L., Cusack, S. V., Vincent, A., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209541 · Cited by 5
Cyclopeptide Inhibitors Target the N‐Terminal Tail of STING and Alleviate Autoinflammation
Wang, X., Cao, A., Zheng, W., & Quan, J. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401253 · Cited by 4
Hawillo, K., Kemiha, S., & Técher, H. (2024) · Onco · doi:10.3390/onco4040022 · Cited by 4
The SLE ‐associated TREX1‐P212fs mutation disrupts ER association leading to type I interferonopathy
Xu, S., Xiao, N., Du, H., Zhou, X., Huang, M., Feng, S., Hu, S., Zhang, X., Zhang, S. J., Cui, D., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202401579r · Cited by 6
“8 Most of the genes associated with type I interferon disorders are closely related to nucleic acid metabolism or sensing, DNA signaling-mediated innate immune responses, and type I interferon receptor signaling.”
RNA sensing at the crossroads of autoimmunity and autoinflammation
Williams, S. G., Sim, S., & Wolin, S. L. (2025) · RNA · doi:10.1261/rna.080304.124 · Cited by 5
“AGS is characterized by high systemic and CNS levels of interferon (Crow and Manel 2015).”
Type I Interferons in Newborns—Neurotoxicity versus Antiviral Defense
Bogunovic, D. (2016) · mBio · doi:10.1128/mbio.00639-16 · Cited by 4
“Patients with mutations of ISG15, USP18, RIG-I, STING, PSMB8, and ACP5 also display systemic features of IFN dysregulation (3, 4).”
BackgroundHuman cGAS Has a Slightly Different Taste for dsDNA
Decout, A. C., & Ablasser, A. (2018) · Immunity · doi:10.1016/j.immuni.2018.08.005 · Cited by 4
Impact des R-loops sur le stress réplicatif induit par les oncogènes dans les cellules cancéreuses
Heuzé, J., Lin, Y., Lengronne, A., Poli, J., & Pasero, P. (2023) · Comptes Rendus Biologies · doi:10.5802/crbiol.123 · Cited by 6
“RNase H2 is frequently mutated in a severe interferonopathy called Aicardi–Goutières syndrome [72,73].”
Vancura, J., Boyd, N. K., Vogel, B. N., Nagesh, D., Ho, E., & Santoro, J. D. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12040-2 · Cited by 4
“Individuals with AGS caused by RNASEH2A make up a minority of those with the condition but are at a significantly higher risk of stroke caused by the development of moyamoya vasculopathy (MMV), which is presumed to be of inflammatory etiology [4–6].”
Bortolin, V., Mansuroglu, Z., Conquet, L., Calcagno, G., Lambert, F., Marin‐Obando, J. P., Segrt, H., Savino, M., Menidjel, R., Souès, S., et al. (2024) · Glia · doi:10.1002/glia.24619 · Cited by 4
Lavin, M. F., & Yeo, A. J. (2021) · Neuron · doi:10.1016/j.neuron.2021.11.019 · Cited by 5
Renson, T., Hamiwka, L. A., & Benseler, S. M. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.931179 · Cited by 4
“It typically involves an early-onset progressive sub-acute encephalopathy associated with developmental delay and seizures, and the occurrence of basal ganglia calcifications and leukodystrophy on CNS imaging (23, 25, 37).”
BackgroundInfluentialBerg, S., Wekell, P., Fasth, A. L., Hawkins, P. N., & Lachmann, H. J. (2016) · Springer eBooks · doi:10.1007/978-3-662-52909-6_7 · Cited by 4
Kouvaraki, M. A., Zerdes, I., Sifakis, E. G., Sarafidis, M., Matikas, A., Tzoras, E., Kjällquist, U., Σταθοπούλου, Κ., Lövrot, J., Alkodsi, A., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35319 · Cited by 3
Just Autoimmunity? The Role of the Innate Immune Response in Lupus
Rodríguez, M. A., & Blasini, A. M. (2025) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000002209 · Cited by 6
10 years in lupus – progress, but not enough
Morand, E. F., & Jones, S. A. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.06.003 · Cited by 3
Miller, C. M., Morrison, J. H., Bankers, L., Dran, R. J., Kendrick, J., Briggs, E., Ferguson, V. L., & Poeschla, E. M. (2025) · mBio · doi:10.1128/mbio.01492-25 · Cited by 3
“In previous studies, phenotypes resembling AGS/SMS were produced by engineering mice to express the MDA5 constitutive activation (GOF) mutants mG821S (75) or huR822Q (76).”
InfluentialWinata, C. A., Hofer, M. J., & Castorina, A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115546 · Cited by 4
“CANDLE syndrome: A closer look at a rare autoinflammatory disorder”
Singh, S., & Sharma, A. K. (2025) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2025.100339 · Cited by 5
“Conversely, individuals with SAVI and CANDLE/PRAAS typically exhibit elevated levels of traditional inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), although AGS patients rarely do [43].”
Marinella, G., Vaia, Y., Politano, D., Galli, J., Nicita, F., Popple, M. M., Pichiecchio, A., Pasquariello, R., Parazzini, C., Pinelli, L., et al. (2026) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2026.109907 · Cited by 3
MDA5 generates compact ribonucleoprotein complexes via ATP-dependent double-stranded RNA unwinding
Quack, S., Maity, S., America, P. P. B., Klein, M., del Valle, A. H., Singh, R., Joiner, J. D., Rashid, Z. M., Smitskamp, Q., Rivas, P., et al. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag274 · Cited by 3
EXOC5/SEC10 attenuates antiviral IFN-I signaling by targeting STING1 for autophagic degradation
Ma, W., Xu, Y., Yu, J., Sun, F., Yu, X. Y., He, L., Li, Y., He, D. C., Wang, H., & He, H. (2026) · Autophagy · doi:10.1080/15548627.2026.2659292 · Cited by 3
“Autosomal dominant gain-of-function mutations in human STING1 cause a severe autoinflammatory syndrome [16,17].”
Cladophorol-A is an inhibitor of cyclic GMP-AMP synthase
Kissai, M., Chin, E. N., Martínez‐Peña, F., Sulpizio, A., Stout, E. P., Usui, I., Barmare, F., Sanchez, B. B., Esquenazi, E., Stanfield, R. L., et al. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.130007 · Cited by 3
Fresh Ideas, Foundational Experiments (FIFE): Immunology and Diabetes 2016 FIFE Symposium
Mouat, I. C., Morse, Z. J., Jean-Baptiste, V. S. E., Allanach, J. R., & Horwitz, M. S. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00238 · Cited by 3
“Type 1 interferonopathies, characterized by a dysfunctional production of type 1 interferons, are often associated with autoinflammation and autoimmune phenomena (27, 28).”
BackgroundThe basic and translational science year in review: Confucius in the era of Big Data
Pisetsky, D. S. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.02.010 · Cited by 3
“interferon production in a condition known as Aicardi-Goutiere syndrome; studies on RNA reveal a similar phenomenon (24).”
BackgroundBankers, L., Miller, C. M., Liu, G., Thongkittidilok, C., Morrison, J. H., & Poeschla, E. M. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901421 · Cited by 2
“Similar GOF mutations in ifih1 as well as mutations in other genes involved in nucleic acid metabolism, antiviral sensing, and IFN induction, cause clinically severe AGS in humans (14, 19).”
BackgroundZhang, L., Ma, J., Jin, X., Zhang, L., Zhang, M., Li, P. Z., Li, J., & Zhang, L. (2022) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2022.0158 · Cited by 3
“IFN-I upregulation was revealed in multiple diseases, including HIV-I chronic infection, type I interferonopathies caused by genetic mutations, Aicardi– Goutie`res syndrome, and SLE (Banchereau and Pascual 2006; Crow and Manel 2015; Cheng and others 2017; Crow and Stetson 2022).”
Adar1 deletion causes degeneration of the exocrine pancreas via Mavs-dependent interferon signaling
Rupani, D. N., Cowan, R. W., Thege, F. I., Chandra, V., Wörmann, S. M., Rajaei, H., Malaney, P., Roux, O. L., Manning, S. L., Hashem, J., et al. (2022) · Development · doi:10.1242/dev.201097 · Cited by 3
NEGATIVE MODULATORS OF THE CGAS-STING PATHWAY
Pike, K. A., Beveridge, R. E., Cyr, P., Skeldon, A. M., Wang, L., & Burch, J. D. (2022) · Medicinal chemistry reviews · doi:10.1021/mc-2022-vol57.ch07 · Cited by 3
Apoptosis and inflammatory forms of cell death
Elkon, K. B., & Oberst, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93232-5.00027-7 · Cited by 3
Ubiquitin-like Proteins in Autoimmune Diseases: Current Evidence and Therapeutic Opportunities
Lee, B., Jeong, H., Kim, Y.-R., Roh, J. S., & Sohn, D. H. (2025) · Immune Network · doi:10.4110/in.2025.25.e21 · Cited by 5
“AGS, a rare inherited autoimmune disease that shares clinical and immunological features with SLE, is classified as a type I interferonopathy (79-81).”
Aicardi‐Goutières syndrome with muscle involvement in early infancy
Deigendesch, N., Morales-Gonzalez, S., Weschke, B., Goebel, H. H., Schuelke, M., & Stenzel, W. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12454 · Cited by 3
Aicardi-Goutières syndrome: Phenotypic and genetic spectrum in a series of three cases
Medinilla, E. E. M., Villagrán‐García, M., Ramírez, M. D. M., Medina, R. C., & Antón, J. M. (2019) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2018.04.011 · Cited by 3
“Type I interferons play a crucial role in the pathogenesis of AGS, in which their expression is upregulated leading to increased production.(3) For this reason, one of the classic laboratory findings in these patients is an elevated level of interferon alfa in CSF, along with pleocytosis and equally elevated levels of…”
BackgroundAsadian, P., & Bienzle, D. (2019) · Viruses · doi:10.3390/v11100921 · Cited by 4
“On the other hand, a high concentration of cytosolic nucleotides can trigger innate immune responses [45].”
BackgroundRNA Editing in Interferonopathies
Frassinelli, L., Galardi, S., Ciafrè, S. A., & Michienzi, A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0787-9_16 · Cited by 4
Síndrome de Aicardi-Goutières: espectro fenotípico y genético en una serie de 3 casos
Medinilla, E. E. M., Villagrán‐García, M., Ramírez, M. D. M., Medina, R. C., & Antón, J. M. (2018) · Anales de Pediatría · doi:10.1016/j.anpedi.2018.04.018 · Cited by 3
Hosseini, S. A., & Labilloy, A. (2019) · StatPearls · Cited by 4
Ebstein, F., Küry, S., Most, V., Rosenfelt, C. S., Scott‐Boyer, M., van Woerden, G. M., Besnard, T., Papendorf, J. J., Studencka‐Turski, M., Wang, T., et al. (2021) · medRxiv · doi:10.1101/2021.12.07.21266342 · Cited by 3
“may seem surprising at first sight, but it is not totally unexpected, since this inconsistency is 627 found in other neurodevelopmental disorders including Aicardi-Goutières [68, 69] and Down 628”
Alternative cGAS signaling promotes herpes simplex encephalitis
Shmuel-Galia, L., Jiang, Z., Stine, L., Cahill, S. E., Ng, S., Wilson, R., Kandasamy, R. K., Kurt‐Jones, E. A., Ramanjulu, J. M., Bertin, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2423873122 · Cited by 3
“One of these diseases, Aicardi–Goutières syndrome (AGS) is an early - onset neurological disorder characterized by constitutive production of type I IFNs and IFN - stimulated genes ( 24 , 25 ).”
Metadata
- Authors
- Crow, Y. J., & Manel, N.
- Affiliations
- Inserm (FR)
- Corresponding author
- Crow, Yanick J.
- Venue
- Nature Reviews Immunology
- Published
- 2015-06-05
- Volume
- 15
- Issue
- 7
- Pages
- 429-440
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W1542158376
- Cited by
- 925
- References
- 106
- Citations by year
- 2026: 63 · 2025: 80 · 2024: 83 · 2023: 92 · 2022: 103 · 2021: 92 · 2020: 82 · 2019: 80 · 2018: 71 · 2017: 88 · 2016: 75 · 2015: 16
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-IDEX-0001, ANR-11-LABX-0043)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- Aicardi-Goutières syndrome, type I interferonopathy, type I interferon, innate immune signaling, monogenic disorders, nucleic acid metabolism, innate immune sensors, interferon induction, interferonopathies, treatment options
- MeSH terms
- Animals, Humans, Interferon Type I, Nervous System Malformations, Autoimmune Diseases of the Nervous System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.